Reuters logo
BRIEF-Camurus: positive top-line results from long-term Phase 3 safety study of CAM2038
May 2, 2017 / 6:15 AM / 7 months ago

BRIEF-Camurus: positive top-line results from long-term Phase 3 safety study of CAM2038

May 2 (Reuters) - CAMURUS AB

* CAMURUS AND BRAEBURN PHARMACEUTICALS ANNOUNCE POSITIVE TOP-LINE RESULTS FROM LONG-TERM PHASE 3 SAFETY STUDY OF CAM2038

* ANNOUNCED POSITIVE TOP-LINE RESULTS FROM A LONG-TERM PHASE 3 TRIAL SUPPORTING SAFETY AND EFFICACY OF CAM2038 IN PATIENTS WITH MODERATE-TO-SEVERE OPIOID USE DISORDER.

* EFFICACY WAS ASSESSED BY WEEKLY AND MONTHLY URINE TOXICOLOGY TESTS

* ON AVERAGE, 75% OF URINE SAMPLES WERE NEGATIVE FOR ILLICIT OPIOIDS ACROSS 48-WEEK TREATMENT PERIOD. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below